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Abstract
The influenza neuraminidase (NA) inhibitors zanamivir, oseltamivir and peramivir were all designed based on the knowledge
that the transition state analogue of the cleaved sialic acid, 2-deoxy,2,3-dehydro N-acetyl neuraminic acid (DANA) was a
weak inhibitor of NA. While DANA bound rapidly to the NA, modifications leading to the improved potency of these new
inhibitors also conferred a time dependent or slow binding phenotype. Many mutations in the NA leading to decreased
susceptibility result in loss of slow binding, hence this is a phenotypic marker of many but not all resistant NAs. We present
here a simplified approach to determine whether an inhibitor is fast or slow binding by extending the endpoint fluorescent
enzyme inhibition assay to a real time assay and monitoring the changes in IC50s with time. We carried out two reactions,
one with a 30 min preincubation with inhibitor and the second without. The enzymatic reaction was started via addition of
substrate and IC50s were calculated after each 10 min interval up to 60 min. Results showed that without preincubation
IC50s for the wild type viruses started high and although they decreased continuously over the 60 min reaction time the
final IC50s remained higher than for pre-incubated samples. These results indicate a slow equilibrium of association and
dissociation and are consistent with slow binding of the inhibitors. In contrast, for viruses with decreased susceptibility,
preincubation had minimal effect on the IC50s, consistent with fast binding. Therefore this modified assay provides
additional phenotypic information about the rate of inhibitor binding in addition to the IC50, and critically demonstrates the
differential effect of incubation times on the IC50 and Ki values of wild type and mutant viruses for each of the inhibitors.
Citation: Barrett S, Mohr PG, Schmidt PM, McKimm-Breschkin JL (2011) Real Time Enzyme Inhibition Assays Provide Insights into Differences in Binding of
Neuraminidase Inhibitors to Wild Type and Mutant Influenza Viruses. PLoS ONE 6(8): e23627. doi:10.1371/journal.pone.0023627
Editor: Ralph Tripp, University of Georgia, United States of America
Received June 11, 2011; Accepted July 21, 2011; Published August 17, 2011
Copyright:  2011 Barrett et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Parts of this work were supported by Grant RO1A1062721 from the NIAID http://www.niaid.nih.gov/Pages/default.aspx, a Pandemic influenza grant
595625 from the NHMRC Australia http://www.nhmrc.gov.au/ and Grant ID 77869 from the MRC UK http://www.mrc.ac.uk/index.htm. The funders had no rolei n
study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: mck245@csiro.au
Introduction
Two licensed neuraminidase (NA) inhibitors (NAIs) are
currently approved globally for the treatment and prevention of
influenza, zanamivir (Relenza
TM) and oseltamivir (Tamiflu
TM). A
third compound peramivir has recently received approval in Japan
and had emergency authorisation for limited use during the
pandemic outbreak [1]. All compounds were designed based on
the knowledge of the structure of sialic acid bound in the NA
active site [2]. The transition state analogue of sialic acid, 2-
deoxy,2,3-dehydro N-acetyl neuraminic acid (DANA) was known
to be a weak inhibitor of the NA. Addition of an amino group at
the 4-position of DANA led to around 100-fold enhancement of
the inhibitory activity whereas the addition of a guanidinium
group (zanamivir) led to around a 10,000-fold enhancement [3].
Addition of the guanidinium group led to zanamivir being a time
dependent, or slow binding inhibitor [3,4]. The hypothesis for the
slow binding of zanamivir is that a water molecule has to be
displaced before the guanidinium group can bind tightly in the
active site [4]. While oseltamivir is also a slow binding inhibitor,
this is thought to be due to the need for the rotation of the E276 in
the enzyme active site [5] to accommodate binding of its
hydrophobic side chain [6–8]. Peramivir contains both the
guanidinium group as in zanamivir, and a hydrophobic side chain
as in oseltamivir. Hence it is also a slow binding inhibitor possibly
impacted by both mechanisms [6]. Some NAs with mutations
conferring resistance to the NAIs appear to have lost this slow
binding phenotype [6,8–11]. Thus in addition to an increase in
IC50, loss of slow binding can also be a phenotypic marker of
reduced susceptibility.
Sensitivity to influenza NAIs is determined by two types of
enzyme inhibition assays, a fluorescent based assay which uses 4-
Methylumbelliferyl N-acetyl-a-D-neuraminic acid (MUNANA)
[12] and a chemiluminescent assay based on the NA-Star substrate
[13,14]. The inhibition assay includes preincubation of NA with its
inhibitor, initiation of the enzymatic reaction by addition of
substrate, and finally addition of a high pH solution which stops
the reaction, and enhances the fluorescent or chemiluminescent
signal. Protocols for the fluorescent assay vary between different
laboratories for the preincubation times and temperatures, assay
incubation time and buffers used, all of which can impact on the
IC50 [14]. Hence there is a need for a standardized assay to enable
comparisons of results between different laboratories. There has
been no study of how incubation times affect IC50s, although Pegg
et al. [4] reported that for binding of zanamivir to an N2 NA the
apparent Ki varied by 10,000-fold depending on the incubation
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kinetics functions means we can continuously monitor changes in
enzyme activity and therefore changes in IC50 with time. We have
now modified the basic MUNANA assay, to a real time assay, and
have developed what we term IC50 kinetics assays. This expands
the information obtained from inhibition assays to also provide
information about the slow or fast binding phenotype of an NA
[11]. Thus this approach provides additional information about
potential NAI resistance and the impacts of mutations on inhibitor
binding. The chemiluminescent assay, commercialised as NA-
StarH (Applied Biosystems), is a rapid reaction, with a substrate
half life of around 15 min, and a very low signal strength
necessitating the addition of an enhancer. Hence this assay
currently does not lend itself to real time analysis. Our aim was to
investigate whether our IC50 kinetics assay could distinguish
differences in binding of the NAIs to a panel of wild type and
known mutants with decreased susceptibility. Our results demon-
strate that this assay can readily distinguish fast and slow binding
of the NAIs, and among the viruses tested the mutant viruses all
demonstrated loss of slow binding compared to the parent wild
type virus.
Methods
Viruses and inhibitors
The wild type and mutant viruses used were: A/Mississippi/03/
01 H1N1 wild type and H274Y mutant with decreased sus-
ceptibility to oseltamivir [15], A/Fukui/45/04 H3N2 wild type
and E119V mutant with decreased susceptibility to oseltamivir
[16], B/Perth/211/01 influenza B wild type and D197E mutant
with decreased susceptibility to all NAIs [17], NWS/G70C H1N9,
a reassortant with the HA of NWS and NA from A/tern/
Australia/G70C/75, wild type and E119G mutant with decreased
susceptibility to zanamivir and peramivir [9,18] and NWS/G70C
R292K mutant with decreased susceptibility to all the NAIs [10].
As an additional comparison for how different N1 NAs behaved in
the assays, we also used an egg cultured and gamma-irradiated
H1N1 pandemic influenza virus (A/Swine/Shepparton/2009).
The original sample for this virus was submitted by the Depart-
ment of Primary Industries, Victoria, Australia to the CSIRO,
Australian Animal Health Laboratory, Diagnostic, Surveillance
and Response group where the virus was cultured. The N1 NAs of
two gamma-irradiated H5N1 viruses were also assayed from a
clade 1 H5N1 virus from Vietnam, and a clade 2 H5N1 virus from
Indonesia [19]. Both clades were included since we have pre-
viously shown that the clade 2 Indonesian viruses had a higher
IC50 for oseltamivir compared to the clade 1 viruses, so we wanted
to see if this was reflected by any differences in the binding
kinetics. DANA was purchased from Sigma (Australia), zanamivir
and peramivir were synthesised by GlaxoSmithKline (Stevenage,
UK) and oseltamivir carboxylate was produced from oseltamivir
phosphate by Dr Keith Watson (Walter and Eliza Hall Institute,
Australia). Dilutions of inhibitors were prepared in water, ranging
from 0.001 nM to 100,000 nM and 7-serial log10 dilutions were
used, the concentrations depended on the wild type or mutant
virus assayed.
Enzyme assays
NA inhibition assays. Viruses were solubilised and
inactivated by the addition of CHAPS (3-[(3-Cholamidopropyl)
dimethylammonio]-1-propanesulfonate) to a final concentration of
1%. We used the fluorescent MUNANA-based assay for all
experiments [12]. Enzyme activity was titrated for all viruses to
ensure linearity of the enzymatic reaction over time. Assays
contained 50 ml of virus or 25 ml of virus+25 ml of inhibitor and
50 ml of 200 mM MUNANA (Carbosynth Berkshire, UK) diluted in
100 mM sodium acetate pH 5.5 and 10 mM CaCl2. We used a
BMG FLUOstar Optima reader and the kinetics function for real
time monitoring of the fluorescent signal. Inhibition assays were
performed in two ways. The first method used a 30 min
preincubation of viruses with serial dilutions of inhibitors followed
by the addition of MUNANA substrate [9]. The second method
added serial dilutions of inhibitors and MUNANA simultaneously
to the NA omitting the pre-incubation step. Fluorescence for both
assays was monitored at 1 min intervals for 60 min after addition of
substrate, to ensure there were no significant fluctuations between
the 10 min data points. Graphs of concentration of inhibitor versus
percent enzyme inhibition compared to the control were plotted
after 10, 20, 30, 40, 50 and 60 min. The IC50 was calculated as the
concentration of inhibitor resulting in a 50% reduction in
fluorescent units (FU) compared to the control. IC50s were then
plotted as bar graphs for each of the time points for both assays.
Alternatively IC50s were also calculated based on the difference in
FU between consecutive 10 min time points, i.e. 10–20, 20–30, 30–
40,40–50and 50–60 minandthe relative rates were plotted against
the drug concentrations. The IC50 was the drug concentration
leading to 50% inhibition of the rate of reaction compared to the
control rate.
Km and Ki
To calculate the Michaelis Menten constant Km, hydrolysis of
MUNANA was measured at substrate concentrations ranging
from 6.25 to 200 mM, with readings taken every minute in the
BMG FLUOstar Optima reader. Experiments were carried out in
duplicate and repeated twice. The maximum slope for each
reaction was determined by comparing the slopes over different
overlapping time intervals. Initial velocities of the reactions were
then calculated by measuring the maximum slopes plotted as a
function of substrate concentrations. The Km was calculated using
a nonlinear regression function in GraphPad Prism. Setting the
constraints of the Km and the substrate concentration at 100 mM,
the Ki was calculated using nonlinear regression and one-site
competitive binding in GraphPad Prism [20].
Results
Kinetics of inhibitor binding
If an inhibitor is time dependent/slow binding, then preincu-
bation of NA in the absence of substrate should increase the
percentage of occupied substrate binding sites, leading to lower
initial IC50 values. Conversely a fast binding inhibitor should
quickly reach equilibrium reducing the impact of preincubation to
a minimum. Wild type and mutant viruses were either
preincubated with 10-fold dilutions of inhibitors for 30 min prior
to the addition of substrate or inhibitors and substrate were added
simultaneously to the virus. Both reactions were continuously
monitored for 60 min. We used DANA as our model for a fast
binding NAI to validate our hypothesis that there should be no
difference with or without preincubation for fast binding NA
inhibitors. Results confirmed that preincubation with DANA did
not affect the relative reaction rates for any of the wild type or
mutant viruses. Figures 1A and B show graphs of NA activity for
the 60 min reactions for A/Fukui/45/04 H3N2 wild type and
DANA.
In contrast to DANA, NA activity curves of viruses incubated
with oseltamivir, zanamivir and peramivir varied between no
preincubation and preincubation reactions, depending on whether
the virus was sensitive or had reduced susceptibility to each
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PLoS ONE | www.plosone.org 2 August 2011 | Volume 6 | Issue 8 | e23627Figure 1. Comparison of the effects of preincubation or no preincubation with inhibitor on the enzyme activity. A/Fukui/45/04 H3N2
wild type virus and E119V mutant virus with reduced oseltamivir susceptibility were incubated in serial dilutions of inhibitors, either with or without
preincubation, to compare the effects on the reaction rates. Left panels no preincubation, right panels 30 min preincubation. (A, B) wild type with
DANA, (C, D) wild type with oseltamivir, (E, F) E119V with oseltamivir, (G, H) E119V with zanamivir. The curves for both reactions for DANA (A, B), and
for E119V with oseltamivir (E, F) show a fairly constant reaction rate, and correlate with fast binding. The differences in the curves with and without
preincubation for oseltamivir binding to wild type virus (C, D) and for zanamivir binding to the E119V mutant (G, H) and the decrease in rates during
the reactions without preincubation, (C, G), are all consistent with a slow binding phenotype.
doi:10.1371/journal.pone.0023627.g001
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observed results for A/Fukui/45/04 H3N2 wild type and E119V
mutant, with reduced oseltamivir susceptibility, are shown in
Figure 1C-H for oseltamivir and zanamivir.
With increasing drug concentrations differences in the shapes
of the curves were noted. Where the target virus was sensitive to
the respective inhibitor, (wild type virus and oseltamivir C, D;
E119V and zanamivir, G, H) the curves showed a decrease in
rate with no preincubation, consistent with the inhibitors binding
slowly, leading to increased inhibition with time. These results are
similar to those originally reported by Pegg et al. in 1994 [21]. In
contrast, after preincubation with inhibitor and addition of
substrate, there was a gradual increase in rate, suggesting some
dissociation of inhibitor. Reaction curves for the E119V mutant
virus incubated with oseltamivir were similar either with or
without preincubation, similar to what we observed with DANA
(Figure 1E, F). This is consistent with rapid binding of oseltamivir
to the E119V mutant.
To examine how these changes in catalysis are reflected in the
respective IC50s over the reaction period, the IC50s were
calculated for consecutive 10 min intervals for DANA, zanamivir,
oseltamivir and peramivir against our panel of wild type and
mutant viruses. Results are shown for each drug and virus
combination in Figures 2 and 3 over the 60 min reaction period.
IC50 kinetics of DANA
For DANA, preincubation with inhibitor did not increase
binding efficacy compared to no preincubation, indicated by the
similar IC50 values in Figure 2 for both reactions with each of the
viruses. Both methods indicated maximum binding occurred
rapidly, surprisingly with an increase in the IC50s over the 60 min
incubation period in both assays. Some reduced susceptibility to
DANA was seen with the B/Perth/211/01 D197E virus
compared to the wild type virus. This mutation affects the
interaction of R152 with the N-acetyl group on the sugar ring [11]
conferring reduced susceptibility to all inhibitors. DANA also
showed reduced binding to the E119G mutant NA, presumably
due to loss of hydrogen bonding between the 49-OH and the
COOH on the E119. Binding to the R292K mutant NA was not
tested for DANA since this mutation also affects binding of all
inhibitors through altered interactions with the C2 COOH group
[5], and would have required concentrations of around 1 mM
DANA. Although blank, this has been left in the graphs to enable
alignment of all the graphs in Figures 2 and 3.
IC50 kinetics of zanamivir
For the viruses known to be sensitive to zanamivir, a 30 min
preincubation step clearly resulted in lower IC50s compared to no
preincubation (Figure 3A). Furthermore, there was a gradual
decrease in IC50 over 60 min without the preincubation step. Both
results are consistent with slow binding. In contrast, for viruses
with reduced susceptibility to zanamivir preincubation did not
enhance binding, since there was very little difference in the final
zanamivir IC50s between the two reactions (Table 1). Without
preincubation the IC50s for B/Perth/211/01 D197E plateaued
rapidly, or for the NWS/G70C E119G and R292K they
increased. This is consistent with the loss of slow binding.
There was an increase in IC50 for all viruses as soon as substrate
was added after preincubation with zanamivir, indicating some
dissociation of inhibitor. The amount of dissociation varied among
the different wild type viruses. IC50s increased over the 60 min by
more than four-fold for the wild type B/Perth/211/01 and Clade
1 H5N1 viruses compared to two-fold or less for many of the other
viruses (Table S1).
Figure 2. Effect of incubation time on IC50s for DANA. Wild type and mutant viruses were preincubated for 30 min with DANA, or virus, DANA
and substrate were co-incubated without a preincubation step. IC50s were calculated after each 10 min up to 60 min, after the addition of the
MUNANA substrate. The IC50s were similar with (+) or without (2) preincubation, correlating with fast binding. Results are the mean of duplicate
assays. Virus abbreviations, wt=wild type, mutants have specific mutation defined. B=B/Perth/211/01, H1N1=A/Mississippi/03/01, H3N2=A/Fukui/
45/04, H1N9=A/NWS/tern/Australia/G70C/75, pH1N1=pandemic H1N1 A/Swine/Shepparton/2009, H5N1 cl1=Vietnam clade 1 H5N1, H5N1
cl2=Indonesian clade 2 H5N1.
doi:10.1371/journal.pone.0023627.g002
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Most viruses sensitive to oseltamivir demonstrated a decrease in
IC50 without preincubation during the 60 min reaction
(Figure 3B). The IC50s were lower after preincubation, although
interestingly the differences in the final IC50s with and without
preincubation were mostly less than seen for the binding of
zanamivir and peramivir, (Table 1). For those viruses with known
reduced susceptibility to oseltamivir, the B/Perth/211/01 D197E,
A/Mississippi/03/01 H274Y, A/Fukui/45/04 E119V, and
NWS/G70C R292K, there was clearly loss of slow binding since
preincubation had minimal effect on decreasing the IC50s
(Figure 3B). Interestingly the reactions discriminated differences
in the apparent dissociation rates for the different inhibitors.
Comparisons of the increases in IC50 between 10 and 60 min after
preincubation showed that in general there was a greater fold
increase for oseltamivir for wild type viruses, compared to
increases seen with zanamivir. Increases with zanamivir were
greater than those seen for peramivir (Table S1). Three wild type
viruses (B/Perth/211/01, Indonesian Clade 2 H5N1 and A/
Swine/Shepparton/ 2009 H1N1) had an intermediate phenotype
for dissociation of oseltamivir. The final IC50s with or without
preincubation were similar (Table 1), indicating they were not slow
binding compared to other wild type viruses. However, the
changes in IC50s over the 60 min time course were different to the
pattern seen with the more resistant mutant viruses (.20-fold
reduced susceptibility). After preincubation the IC50s of these
mutant viruses were already high and there were only small
increases in the IC50s over 60 min. In contrast, these three wild
type viruses had an initial lower IC50 after preincubation, but
there was more than a 10-fold increase in IC50 over the 60 min
reaction time (Table S1). Therefore by following the changes over
time we have identified differences in the apparent dissociation
which would not have been obvious from the standard single end
point IC50s.
IC50 kinetics of peramivir
For all the wild type viruses preincubation with peramivir
enhanced inhibition (Figure 3C). IC50s for most wild type viruses
were more than 8-fold lower than without preincubation
(Table 1). Decreases in IC50s were seen without preincubation
during the 60 min reaction. For most wild type viruses without
preincubation there was a greater change in IC50 during the
60 min reaction for peramivir than zanamivir, with the least
change seen in the oseltamivir reactions (Table S1). This is the
reverse seen for the preincubation reaction, and would relate to
the very slow binding of peramivir compared to the other two
inhibitors [22–24]. We also saw loss of slow binding with those
viruses with reduced susceptibility to peramivir, which include
the B/Perth/211/01 D197E, the A/Mississippi/03/01 H274Y,
the NWS/G70C E119G, and R292K. As seen for the B/Perth/
211/01 D197E with the other inhibitors, without preincuba-
tion there was a rapid plateau in IC50s. For the other mutant
viruses some dissociation was seen in the reactions without
preincubation.
Table 1. Comparison of final IC50 (nM) values of reactions with and without preincubation after 60 min
a.
bB/Perth
wt
B/Perth
D197E
Miss’pi
H1N1
wt
Miss’pi
H1N1
H274Y
Fukui
H3N2
wt
Fukui
H3N2
E119V
5H1N9
wt
G70C
H1N9
E119G
G70C
H1N9
R292K
Swine
pH1N1
Avian
H5N1
Clade1
Avian
H5N1
Clade2
Zanamivir No pre 167 434 7.8 6.0 32.4 51.9 5.7 816 110 5.8 12.0 11.2
309 pre 8.9 258 1.9 2.2 3.8 3.4 2.7 678 94.8 1.4 2.5 1.3
No pre/pre 18.8 1.7 4.1 2.7 8.5 15.3 2.1 1.2 1.2 4.2 4.7 8.6
Oseltamivir No pre 144 660 7.3 2353 5.3 208 4.0 5.4 30139 6.8 4.1 21.4
309 pre 104 708 3.1 2440 1.7 260 2.8 2.9 24692 5.1 0.6 19.6
No pre/pre 1.4 0.9 2.4 1.0 3.2 0.8 1.5 1.9 1.2 1.3 7.4 1.1
Peramivir No pre 27.8 75.2 3.1 196 11.9 21.4 1.2 14.6 261 2.0 6.2 5.4
309 pre 2.8 41.5 0.4 153 1.3 2.1 0.4 13.3 260 0.3 0.3 0.6
No pre/pre 9.8 1.8 8.2 1.3 9.0 10.2 3.2 1.1 1.0 7.1 21.0 9.3
aIC50 values are the average of duplicate assays.
Viruses, wt=wild type, mutants have specific mutation defined. B/Perth/211/01, A/Mississippi/03/01, A/Fukui/45/04, A/NWS/tern/Australia/G70C/75, pandemic H1N1 A/
Swine/Shepparton/2009, Vietnam clade 1 avian H5N1, Indonesian clade 2 avian H5N1.
doi:10.1371/journal.pone.0023627.t001
Figure 3. Effect of incubation time on IC50s for zanamivir, oseltamivir and peramivir. Wild type and mutant viruses were preincubated for
30 min with inhibitor (+) before addition of substrate, or virus, inhibitor and substrate were all co-incubated without a preincubation step (2). IC50s
were calculated after addition of substrate for each 10 min up to 60 min. (A) Final higher IC50 values for binding of zanamivir without preincubation
compared to preincubation and the decreases in IC50s without preincubation over the 60 min correlate with slow binding. For D197E, E119G and
R292K final 60 min values are similar for both reactions, which indicate loss of slow binding and correlates with reduced susceptibility to zanamivir.
(B) For oseltamivir final higher IC50 values for reactions without preincubation compared to preincubation and decreases in IC50s without
preincubation indicate slow binding to wild type viruses. For D197E, H274Y, E119V, R292K final 60 min values are similar which indicates loss of slow
binding and correlates with reduced susceptibility to oseltamivir. (C) For peramivir final higher IC50 values for reactions without preincubation
compared to preincubation, and decreases in IC50s without preincubation indicate slow binding. For D197E, H274Y, E119G and R292K final 60 min
values are similar for both reactions, which indicate the loss of slow binding and correlates with reduced susceptibility to peramivir. Results are means
of duplicate assays. R=reduced susceptibility. Virus abbreviations, wt=wild type, mutants have specific mutation defined. B=B/Perth/211/01,
H1N1=A/Mississippi/03/01, H3N2=A/Fukui/45/04, H1N9=A/ /NWS/ Tern Australia/ /70, pH1N1=pandemic H1N1 A/Swine/Shepparton/2009, H5N1
cl1=Vietnam clade 1 H5N1, H5N1 cl2=Indonesian clade 2 H5N1.
doi:10.1371/journal.pone.0023627.g003
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Traditionally the IC50 is calculated based on the relative FU for
the control and drug treated samples at the end of a 45–60 min
reaction period. As the IC50 is calculated based on the total FU, it
actually represents the average enzyme inhibition up to that time
point. This approach assumes the percent inhibition, and thus
IC50 is constant for the entire period.
However, our results have shown when inhibitors are slow
binding the reaction rates change more during the early parts of
the reaction, but may stabilize and become more constant later in
the reaction. Therefore, the analysis of IC50s based on reaction
rates in separate time intervals, where each IC50 is independent of
the preceding interval, might represent a more appropriate way to
investigate the potency of an NAI. Rates were calculated based on
the difference in FU between each 10 min. IC50s were calculated
as the drug concentration causing 50% inhibition of the rate of the
control reaction. In Table 2 we show how the IC50s compare
based on the FU method or the rate method for the A/
Mississippi/03/01 and A/Fukui/45/04 wild type viruses. With
both methods the IC50s changes during the reaction, and there is
up to a two-fold difference between the two methods after 60 min.
The IC50s based on cumulative FU are all higher than the IC50s
based on rates without preincubation and lower in the preincu-
bation assays. As our data indicates that the reaction becomes
more stable in the final intervals, the IC50s calculated for the last
interval may be more accurate than the IC50 based on total FU,
since it is not using the data from the preceding intervals.
However, this means kinetics assays would have to be used in
order to calculate the rates between time intervals. Hence while
potentially more accurate for slow binding inhibitors, this
approach is more time consuming for routine testing of large
numbers of isolates, when compared to calculating IC50s based on
the final FU value.
Effect of reaction time on Ki
Other groups also use the Ki as it is thought not to vary as much
as the IC50 with different reaction conditions, namely the substrate
concentration. We used two approaches to calculate the Ki; the
first calculated Kis for cumulative times (10–209, 10–309 etc.),
which is similar to single time points used by others, (e.g. a 45 or
60 min reaction) and the second calculated Kis for each
consecutive 10 min time interval (10–209, 20–309 etc.). The Km
values were calculated for the A/Mississippi/03/01 wild type
(15 mM) and H274Y mutant (27.6 mM), and these were used to
calculate the Ki values in GraphPad Prism. Results are shown in
Figure 4A and B. For the mutant virus the Ki values for oseltamivir
changed little over the course of the reaction with or without
preincubation. For wild type viruses these Ki values changed with
time in both methods with or without preincubation. This is not
surprising since the reaction rates were constantly changing
(exemplified by A/Fukui/45/04 in Figure 1), and the Ki depends
on the reaction rate for each time interval. For oseltamivir and the
wild type virus there was little change in the Ki after 40 min. For
zanamivir the Kis continued to change through the 60 min period,
indicating that the steady state had not yet been reached. The
changes in Ki were less for the cumulative method since this
averages the rates up to that time, whereas the Kis for consecutive
time intervals are independent of the rates for preceding times.
This data shows that although Ki is considered more invariant with
regard to assay conditions it is affected in the same way as IC50sb y
the changing reaction rate over time.
Discussion
We have shown here that a simple extension of the standard NA
enzyme inhibition assay, to a real time IC50 kinetics assay provides
an insight into whether mutations affect the kinetics of drug
binding, without the need for complicated equations. The assay
can be carried out in any laboratory with a filter based fluorimeter,
and kinetics programs, hence requires no additional equipment or
software. By comparing the assay with and without preincubation
with inhibitor we demonstrated that preincubation enhances
inhibitor binding to wild type viruses, but has minimal effect on
inhibitor binding to many viruses with reduced susceptibility to the
NAIs, known to have lost the slow binding phenotype.
Importantly, loss of slow binding is only seen for the drug to
which the virus has reduced susceptibility. For example while we
see loss of slow binding of both oseltamivir and peramivir to the
H274Y virus, this has no impact on the binding kinetics of
zanamivir to which the virus remains sensitive. Conversely we see
loss of slow binding only of zanamivir and peramivir to the E119G
Table 2. Differences in IC50 (nM) calculated on relative slope between time intervals
a versus total fluorescent units
b for A/
Mississippi/03/01 and A/Fukui/45/04 wild type viruses.
A/Mississippi/03/01 A/Fukui/45/04
FU time point 0–20 0–30 0–40 0–50 0–60 0–20 0–30 0–40 0–50 0–60
Zanamivir no pre 16.4 12.8 10.1 8.6 7.8 106.0 58.6 44.4 36.7 32.4
Zanamivir pre 1.0 1.3 1.5 1.7 1.9 3.1 3.5 3.6 3.7 3.8
Oseltamivir no pre 9.1 7.6 7.4 7.2 7.3 14.5 8.8 6.6 5.8 5.3
Oseltamivir pre 1.0 1.8 2.4 2.8 3.1 0.6 0.8 1.1 1.4 1.7
Rates time interval 10–20 20–30 30–40 40–50 50–60 10–20 20–30 30–40 40–50 50–60
Zanamivir no pre 16.0 8.3 6.0 5.5 5.0 47.5 54.3 25.3 19.7 17.3
Zanamivir pre 1.1 1.8 2.3 2.6 3.4 3.2 4.4 3.8 4.2 4.5
Oseltamivir no pre 7.5 6.2 6.7 6.8 7.9 7.2 4.7 3.8 3.8 3.4
Oseltamivir pre 2.3 3.9 4.6 5.0 5.6 0.9 1.7 2.5 3.3 3.4
aIC50s for FU are based on the drug concentration resulting in 50% inhibition of the uninhibited control FU.
bRates in FU/min are calculated for each drug concentration for each time interval and the IC50 is the drug concentration which inhibits the rate of the uninhibited
control by 50%. This approach separates each reaction time so it is independent of the rates of preceding time intervals.
doi:10.1371/journal.pone.0023627.t002
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peramivir, but is sensitive to oseltamivir.
We also identified three wild type viruses with an intermediate
phenotype, with similar final IC50s with or without preincubation,
contrary to what is expected if they are slow binding (B/Perth/
211/01, Indonesian Clade 2 H5N1 and A/Swine/Shepparton/
2009 pandemic H1N1). Unlike the mutant viruses where the IC50s
did not change much during the reactions, these viruses showed
more than a 10-fold increase in IC50 in the preincubation reaction.
This was much greater than for other wild type viruses.
Interestingly similar phenotypes with greater than 10-fold
increases in IC50s after preincubation were also seen with
zanamivir and peramivir binding to the B/Perth/211/01 D197E
mutant, thus suggesting these three wild type viruses have a low
level of resistance. Dissociation studies of inhibitors are tradition-
ally carried out by incubating virus or NA with excess inhibitor,
removing unbound inhibitor by the use of a column, then
following the enzyme activity [6,22–24]. Our IC50 kinetics assays
with the preincubation step indicate that despite the continued
presence of inhibitor in the assay mixture, some dissociation occurs
upon addition of substrate. Interestingly different relative dissoci-
ation rates can be distinguished between different inhibitors and
different viruses. Also surprising was that without preincubation
we saw rapid dissociation for DANA for all viruses and for most of
the mutants with the drug to which they had reduced sus-
ceptibility. A possible explanation for this might be that while the
inhibitor and substrate both bind rapidly, due to the higher affinity
of the inhibitors they initially bind faster than the substrate. Then
due to the higher substrate concentration this gradually displaces
the inhibitor, leading to an increase in IC50.
While ‘‘slow’’ or ‘‘fast’’ binding are phenotypic markers of NA
behaviour it is obvious that the final 60 min IC50s for the mutant
viruses either with or without preincubation are similar. We have
therefore done a semi-quantitative comparison. In general for all
mutant viruses (except the NWS/G70C) the differences in the
60 min IC50s between no preincubation and preincubation were
less than 2-fold for zanamivir, less than 1.5-fold for oseltamivir,
and less than 2-fold for peramivir. Although the differences for the
60 min IC50s between the no preincubation and preincubation for
NWS/G70C N9 were less than for other viruses, indicating that
inhibitor binding is more rapid, there was still a larger difference
for the wild type compared to the mutant virus.
It is well established that influenza B viruses are less sensitive to
oseltamivir in enzyme assays [25]. There are also reports of lower
clinical efficacy of oseltamivir in children infected with influenza B,
compared to influenza A [26]. We have recently shown that the
structural rearrangements of the E276, necessary for high affinity
bindingforoseltamivirdo not appeartooccurininfluenzaB.Thisis
consistent with lack of slow binding and higher IC50s seen for
influenza B viruses [11]. Similarly the faster binding of oseltamivir
to the clade 2 H5N1 virus correlates with the higher IC50 [19].
Structurally this correlates with an H252Y difference between clade
1 andclade2 NAs,which alsopreventsfull rotationoftheE276 [27]
in the clade 2 virus. Hence the difference in binding kinetics is
consistent with the known reduced susceptibility of both of the
influenza B and clade 2 H5N1 wild type viruses to oseltamivir.
While the apo structure of the pandemic N1 NA is known [28] the
structure of the complex with oseltamivir has not yet been
published. Since structural changes occur upon binding oseltamivir
wecannotpredictifthereisanystructuralcorrelationtoitsapparent
faster binding/dissociation to the pandemic H1N1 NA.
These results also demonstrate that there are factors other than
the displacement of a water molecule by the guanidino group of
zanamivir, or the rotation of the E276 for oseltamivir and
peramivir that lead to slow binding of the NA inhibitors. The
D197E mutation in the B/Perth/211/01 virus leads to altered
interactions of the R152 with the N-acetyl group on the inhibitors,
having no impact in the region of the guanidinium group or the
rotation of the E276 [11] yet it leads to loss of slow binding.
Characterisation of different mutants will help provide more
understanding of factors involved in the slow binding of the NA
inhibitors and what are the key interactions needed for high
affinity binding other than those already identified. This
information may be useful for design of new inhibitors.
Figure 4. Effect of incubation times on Ki values for A/
Mississippi/03/01 H1N1 wild type and H274Y mutant viruses.
Ki values were calculated either (A) for the cumulative reaction time or
(B) for each successive 10 min interval using the relative reaction rates
in GraphPad Prism. For viruses sensitive to an inhibitor the Ki values
changed over the course of the reaction. In contrast, for the H274Y virus
binding to oseltamivir to which it has reduced susceptibility, the Ki
stabilized more rapidly. Since the Kis in (A) are calculated based on the
average rates there is less change than in (B) where each interval Ki is
independent of the preceding rates. Hence in addition to the
incubation time having a differential effect on the Ki values for wild
type and mutant viruses, the time range used for the Ki calculations also
affects the value. Results are means of duplicate assays. Z-zanamivir,
O –oseltamivir (+) preincubation with inhibitor, (2) no preincubation.
doi:10.1371/journal.pone.0023627.g004
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fold resistance of a mutant, such as use of the fluorescent or
chemiluminescent assay and concentration of substrate [14,25].
All inhibitors appeared to dissociate after preincubation with
inhibitor on the addition of substrate, however there were different
rates of dissociation for different viruses and inhibitors. Oseltami-
vir dissociated faster in many wild type viruses compared to the
other two drugs, whereas dissociation of peramivir was very slow,
consistent with observations by the classical methods demonstrat-
ing slow dissociation [22–24]. Hence longer reaction times will
result in greater increases in the oseltamivir IC50s compared to
increases in the IC50s of the other inhibitors. Because there is less
change in the reaction rates with the mutant viruses their IC50 and
Ki values were not as affected by the incubation or reaction times.
However, our results here and previously published [11] clearly
demonstrate that incubation time is an important factor which can
affect both the IC50 and Ki differently for wild type and mutant
viruses. Furthermore different incubation times in different
laboratories would affect comparisons of the fold difference of
wild type and mutant viruses. Understanding which variables
affect the IC50s and Kis could ultimately lead to a better
understanding of what is needed for a standardized assay to
facilitate direct comparisons of isolates between different labora-
tories.
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